Now showing items 1-2 of 2

    • A phase I study of ABT-510 plus bevacizumab in advanced solid tumors. 

      Uronis, Hope E; Cushman, Stephanie M; Bendell, Johanna C; Blobe, Gerard C; Morse, Michael A; Nixon, Andrew B; Dellinger, Andrew; ... (13 authors) (Cancer Med, 2013-06)
      Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT-510 is a synthetic analog ...
    • Development of a Novel c-MET-Based CTC Detection Platform. 

      Zhang, Tian; Boominathan, Rengasamy; Foulk, Brad; Rao, Chandra; Kemeny, Gabor; Strickler, John H; Abbruzzese, James L; ... (20 authors) (Mol Cancer Res, 2016-06)
      UNLABELLED: Amplification of the MET oncogene is associated with poor prognosis, metastatic dissemination, and drug resistance in many malignancies. We developed a method to capture and characterize circulating tumor cells ...